Off-label treatment for alcohol use disorder is linked to slower liver decline, study suggests

WASHINGTON — There are three FDA-approved drugs for treating alcohol use disorder. But a different medication, one frequently used off-label for the condition, could provide greater benefit to patients with alcohol-associated liver disease, a new study suggests. 

The data, presented this week as an abstract at Digestive Disease Week in D.C., suggest anti-seizure gabapentinoids might be a simple and effective treatment for slowing the progression of alcohol-associated liver disease. Nearly 30 million adults in the United States have alcohol use disorder, according to the 2022 National Survey on Drug Use and Health. 

Read the rest…